OptimizeRx (NASDAQ:OPRX) Issues Earnings Results

OptimizeRx (NASDAQ:OPRX) announced its quarterly earnings data on Wednesday. The company reported $0.13 earnings per share for the quarter, missing the consensus estimate of $0.16 by ($0.03), Zacks reports. OptimizeRx had a return on equity of 9.44% and a net margin of 4.66%.

OptimizeRx Stock Performance

Shares of OptimizeRx stock traded down $0.40 on Wednesday, reaching $8.95. 365,145 shares of the company were exchanged, compared to its average volume of 350,150. The company has a debt-to-equity ratio of 0.14, a quick ratio of 5.58 and a current ratio of 5.58. The company’s 50-day moving average is $8.40 and its two-hundred day moving average is $7.25. The firm has a market cap of $168.58 million, a price-to-earnings ratio of 38.91 and a beta of 1.20. OptimizeRx has a 1-year low of $4.54 and a 1-year high of $16.37.

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on the company. Citizens Jmp raised their price objective on OptimizeRx from $9.00 to $11.00 and gave the stock a “market outperform” rating in a research note on Friday, August 14th. Wall Street Zen lowered shares of OptimizeRx from a “strong-buy” rating to a “buy” rating in a research note on Monday, July 20th. Citigroup reissued a “market outperform” rating on shares of OptimizeRx in a report on Tuesday, October 27th. UBS Group set a $11.00 target price on shares of OptimizeRx in a report on Friday, August 14th. Finally, Weiss Ratings upgraded shares of OptimizeRx from a “sell (d)” rating to a “sell (d+)” rating in a research report on Tuesday, August 25th. Six investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, OptimizeRx has a consensus rating of “Moderate Buy” and a consensus price target of $11.57.

OptimizeRx Company Profile

OptimizeRx Corporation (NASDAQ: OPRX) is a digital health and life sciences technology company that helps pharmaceutical and biotechnology companies connect with healthcare professionals and patients. Its platform supports prescription-related communications, treatment access, affordability, adherence and patient engagement throughout the medication journey. The company provides solutions that can be integrated into electronic health records and other healthcare workflows. Its offerings include point-of-care messaging for healthcare professionals, patient support and savings programs, medication access tools, and data and analytics services designed to help life sciences companies communicate with relevant audiences and understand engagement.